BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 17102124)

  • 1. Pathology of pheochromocytoma and extra-adrenal paraganglioma.
    Tischler AS; Kimura N; Mcnicol AM
    Ann N Y Acad Sci; 2006 Aug; 1073():557-70. PubMed ID: 17102124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pheochromocytoma and extra-adrenal paraganglioma: updates.
    Tischler AS
    Arch Pathol Lab Med; 2008 Aug; 132(8):1272-84. PubMed ID: 18684026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pheochromocytoma and sympathetic paragangliomas].
    Zollinger R; Hedinger C
    Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsporadic cases and unusual morphological features in pheochromocytoma and paraganglioma.
    Lamovec J; Frković-Grazio S; Bracko M
    Arch Pathol Lab Med; 1998 Jan; 122(1):63-8. PubMed ID: 9448019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Malignant pheochromocytoma. A case report and comments on a rare pathology].
    Boneschi M; Erba M; Rinaldi P; Cusmai F; Miani S
    Minerva Chir; 1999; 54(1-2):73-8. PubMed ID: 10230231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.
    Korpershoek E; Stobbe CK; van Nederveen FH; de Krijger RR; Dinjens WN
    Endocr Relat Cancer; 2010 Sep; 17(3):653-62. PubMed ID: 20488782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas.
    Pang LC; Tsao KC
    Arch Pathol Lab Med; 1993 Nov; 117(11):1142-7. PubMed ID: 8239937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental gene expression of sympathetic nervous system tumors reflects their histogenesis.
    Hoehner JC; Hedborg F; Eriksson L; Sandstedt B; Grimelius L; Olsen L; Påhlman S
    Lab Invest; 1998 Jan; 78(1):29-45. PubMed ID: 9461120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal and extra-adrenal nonfunctioning composite pheochromocytoma/paraganglioma with immunohistochemical ectopic hormone expression: comparison of two cases.
    Gong J; Wang X; Chen X; Chen N; Huang R; Lu C; Chen D; Zeng H; Zhou Q
    Urol Int; 2010; 85(3):368-72. PubMed ID: 20829582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of adrenal tumors.
    Opocher G; Schiavi F; Cicala MV; Patalano A; Mariniello B; Boaretto F; Zovato S; Pignataro V; Macino B; Negro I; Mantero F
    Minerva Endocrinol; 2009 Jun; 34(2):107-21. PubMed ID: 19471236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumors of the adrenal medulla and the paraganglia].
    Klöppel G
    Pathologe; 2003 Jul; 24(4):280-6. PubMed ID: 14513275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paragangliomas: etiology, presentation, and management.
    Joynt KE; Moslehi JJ; Baughman KL
    Cardiol Rev; 2009; 17(4):159-64. PubMed ID: 19525677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignancy in pheochromocytomas.
    Salmenkivi K; Heikkilä P; Haglund C; Arola J
    APMIS; 2004 Sep; 112(9):551-9. PubMed ID: 15601303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma.
    Tischler AS; deKrijger RR
    Endocr Relat Cancer; 2015 Aug; 22(4):T123-33. PubMed ID: 26136457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
    Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
    Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phaeochromocytoma: a catecholamine and oxidative stress disorder.
    Pacak K
    Endocr Regul; 2011 Apr; 45(2):65-90. PubMed ID: 21615192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas.
    McNicol AM
    Endocr Pathol; 2006; 17(4):329-36. PubMed ID: 17525481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.